Insiders Trades
Acadia Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 May 2023.
Acadia Pharmaceuticals Inc: what insiders have been doing
Headquartered in San Diego, United States, Acadia Pharmaceuticals Inc belongs to the Healthcare & Pharma sector and traces its origins to 1993. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 38 filings signed by 14 insiders.
There is no open-market purchase to report; the filings show 13 sales worth €1.9M by 5 insiders. The amount is not disclosed for 1 filing. Daly James M filed the largest sale, €581k, on 12 November 2025.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 38 filings, this issuer sits above that mark. The full history, which starts in 2016, counts 5 purchases against 65 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 1.07 bn USD and net income at 391.0 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
216
Thresholds
n/a
Buy Volume
€172,971
5 ops. · all time
Sell Volume
€9M
65 ops. · all time
Who traded when
BuySaleMark C. Schneyer11 sales
James Kihara8 sales
Elizabeth A. Garofalo2 sales
Elizabeth H.Z. Thompson2 sales
James M. Daly1 sale
Laura Brege1 sale
+2 other insiders
Since the insiders bought
- -37.8%Entry US$24.45 · Close at T+365 US$15.20
- +20.6%Entry US$27.11 · Close at T+365 US$32.69
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Acadia Pharmaceuticals Inc Buy (bullish), based on 19 analysts. Average price target: US$30.53.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,910 of 24,148 companies
72.1
score / 100
Value53
Quality91
FCF yld3.1%
Earn yld12%
EV/EBITDA29.4x
ROE36%
Gross mgn92%
Net mgn36%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.71
Analyst consensus
19 analystsBuy
US$16.00Target US$30.53(+55%)US$37.00
Income statement
RevenueUS$1.1B
Gross profitUS$982.5M92% margin
EBITDAUS$116.6M11% margin
Net incomeUS$391M33.4% margin
Valuation
PER (trailing)8.8x
PER (forward)21.4x
P/Book2.6x
Beta0.89
Balance sheet & cash
Market capUS$3.4B
Total debtUS$52.2M
Free Cash FlowUS$105.1M
Debt / Equity6%
Profitability & ownership
ROE35.7%
ROA3.6%
% insiders0.3%
% institutions99.7%
Last declaration on 7 August 2026
Declarations216 total
5,849 shares@ US$17.840.0029% mcap3.7% of flowCommon StockSEC:0001899977-26-000008:0
5,849 shares@ US$29.00290.0047% mcap6.0% of flowCommon StockSEC:0001899977-26-000008:1
9,292 shares@ US$29.33750.0076% mcap9.6% of flowCommon StockSEC:0001899977-26-000008:4
14,292 shares@ US$17.840.0071% mcap9.0% of flowCommon StockSEC:0001899977-26-000008:2
5,000 shares@ US$29.000.0040% mcap5.1% of flowCommon StockSEC:0001899977-26-000008:3
5,849 shares@ US$27.150.0044% mcap5.6% of flowCommon StockSEC144:0001967940-26-000042
32,272 sharesCommon StockSEC:0001861477-26-000005:0
16,508 shares@ US$26.130.012% mcap99.7% of flowCommon StockSEC:0001861477-26-000005:1
50 shares@ US$26.170.0000% mcap0.3% of flowCommon StockSEC:0001861477-26-000005:2
11,421 sharesCommon StockSEC:0001816160-26-000009:0
11,421 shares@ US$26.00470.0066% mcap33.9% of flowCommon StockSEC144:0001967940-26-000036
18,622 shares0Common StockSEC:0001193125-26-253632:0
18,622 shares0Common StockSEC:0001193125-26-253632:1
8,107 sharesCommon StockSEC:0001177917-26-000009:0
8,107 sharesCommon StockSEC:0001365619-26-000002:0
8,107 sharesCommon StockSEC:0001560782-26-000002:0
2,010 sharesCommon StockSEC:0001604689-26-000009:0
8,107 sharesCommon StockSEC:0001826361-26-000002:0
5,401 shares@ US$21.180.0022% mcap12.8% of flowCommon StockSEC:0001816160-26-000008:0
3,506 shares@ US$21.790.0014% mcap2.7% of flowCommon StockSEC:0001899977-26-000007:1
1,332 shares@ US$21.790.0005% mcap3.2% of flowCommon StockSEC:0001816160-26-000007:1
2,596 sharesCommon StockSEC:0001816160-26-000007:0
6,815 sharesCommon StockSEC:0001899977-26-000007:0
1,030 shares@ US$22.200.0004% mcap2.5% of flowCommon StockSEC:0001816160-26-000005:1
25 of 216 declarations
About Acadia Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq under the ticker ACAD, making it a closely watched name for investors focused on U.S. specialty healthcare and neuroscience. Headquartered in San Diego, California, the company develops and commercializes therapies for neurological disorders and rare diseases, with a strategy centered on underserved patient populations where treatment options are limited. Its corporate identity is rooted in neuroscience innovation and long-standing expertise in central nervous system disorders. ([acadia.com](https://acadia.com/en-us/about?utm_source=openai))
Acadia’s commercial portfolio is anchored by two key products. NUPLAZID (pimavanserin) is described by the company as the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. DAYBUE (trofinetide) is its second major commercial franchise: it is approved for Rett syndrome in adult and pediatric patients two years of age and older, with commercialization in the United States and Canada, and regulatory efforts underway in Europe. In December 2025, the FDA approved DAYBUE STIX, a powder formulation of trofinetide, and the product is now broadly available in the United States, adding convenience and formulation flexibility that may support adoption and persistence. ([acadia.com](https://acadia.com/en-us?utm_source=openai))
Read moreShow less
From a competitive standpoint, Acadia stands out as a focused neuroscience and rare-disease company. That specialization gives it meaningful scientific, regulatory and commercial barriers to entry, but also creates concentration risk because the business depends heavily on a small number of key assets. Recent company disclosures indicate that momentum has strengthened materially: 2025 total revenue exceeded $1 billion, and management raised 2026 guidance, signaling a more durable commercial base. In the first quarter of 2026, the company reiterated full-year guidance while reporting continued revenue growth. ([acadia.com](https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operating-overview?utm_source=openai))
Geographically, Acadia remains primarily U.S.-focused, but it is building an international footprint through Canada, Europe and certain named-patient or access pathways outside the U.S. The company is also actively advancing its pipeline, including remlifanserin for Alzheimer’s disease psychosis, ACP-711 for essential tremor, and additional CNS-focused programs. For French-speaking investors, ACAD therefore represents a specialty healthcare equity with a mix of established commercial assets, regulatory expansion potential, and clinical catalysts. ([acadia.com](https://acadia.com/en-us/about?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
